NovaBay Pharmaceuticals (NBY) shares were up 77% premarket Friday after the company said it signed a deal to sell its Avenova brand and assets to an Acumen Health unit for $9.5 million in cash.
The transaction is expected to close in Q4, subject to approval by NovaBay shareholders and customary closing conditions.
Price: 0.8796, Change: +0.38, Percent Change: +77.02
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments